Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
2022 · Journal of Clinical Oncology · 327 citations
https://doi.org/10.1200/jco.21.02660
F
Fernando Franco
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
108
Papers
1.8K
Citations
20
h-index
32
i10-index
Fernando Franco is an academic researcher from MD Anderson Cancer Center Madrid. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Diagnosis and Treatment & Cancer Genomics and Diagnostics. The author has an h-index of 20, co-authored 92 publications.
ORCID: 0000-0001-8964-5136Papers by this author
worksCisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition
2019 · Free Radical Biology and Medicine · 207 citations
https://doi.org/10.1016/j.freeradbiomed.2019.03.009
Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor–positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment
2021 · European Journal of Cancer · 31 citations
https://doi.org/10.1016/j.ejca.2021.02.031
Chronodisruption and Ambulatory Circadian Monitoring in Cancer Patients: Beyond the Body Clock
2022 · Current Oncology Reports · 11 citations
https://doi.org/10.1007/s11912-021-01158-z
Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data
2021 · BMC Cancer · 10 citations
https://doi.org/10.1186/s12885-021-08713-8
Immunogenicity of COVID-19 vaccines in lung cancer patients
2023 · Lung Cancer · 9 citations
https://doi.org/10.1016/j.lungcan.2023.107323
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat